ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma

Liu, Jia; Nie, Chunsheng*哈尔滨医科大学
Anti-Cancer Drugs2022-10DOI: 10.1097/CAD.0000000000001329
6被引4阅读
引用收藏
分享

摘要

Lysine-specific demethylase 5B (KDM5B) exerts its tumor-promoting functions in numerous malignancies, although the possible mechanisms by which KDM5B promotes cancer aggressiveness in hepatocellular carcinoma (HCC) have been preliminarily explored, the role of this gene in regulating sorafenib-resistance in HCC has not been studied. Thus, the present study was designed to resolve this problem, and our data suggested that KDM5B was significantly upregulated in the HCC tissues collected from patients with sorafenib treatment history. Consistently, continuous low-dose sorafenib administration increased KDM5B expression levels in the sorafenib-resistant HCC cells compared to their sorafenib-sensitive counterparts. Next, by performing the functional experiments, we found that KDM5B positively regulated sorafenib-resistance and cancer stem cell (CSC) properties in HCC cells in vitro and in vivo. Furthermore, upregulation of KDM5B-degraded phosphatase and tensin homolog (PTEN), results in the activation of the downstream oncogenic PI3K/Akt pathway. Subsequently, the rescuing experiments verified that the promoting effects of KDM5B overexpression on chemoresistance and cancer stemness in HCC cells were all abrogated by PI3K (p110) knockdown and PTEN overexpression. Collectively, those data hinted that KDM5B influenced CSC properties and sorafenib-resistance in HCC cells through modulating the PTEN/PI3K/Akt pathway, and KDM5B could be used as a potential target for the treatment of HCC in clinic.

学科与关键词

关键词
hepatocellular carcinomaKDM5BPTENP13KAkt pathwaystem cell propertiessorafenib-sensitivity
相关
加载中…
  • FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma
    Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
  • Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway
    Li, Xiaodong; Yin, Xuedong; Bao, Heyi; Liu, Chang*Molecular and Cellular Probes, 2023, 67: 101877.被引 3
  • ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
    Huang, Wenbin; Chen, Kunling; Lu, Yishi; Zhang, Donghui; Cheng, Yuan; Li, Liuran; Huang, Weimei; He, Guolin; Liao, Hangyu; Cai, Lei; Tang, Yujun; Zhao, Liang*; Pan, MingxinNeoplasia, 2021, 23(12): 1227-1239.被引 59
查看全部 →

发表信息

论文状态
公开发表
期刊
Anti-Cancer Drugs
发表日期
2022-10
卷期
第 33 卷, 第 9 期
页码
840-849
DOI
10.1097/CAD.0000000000001329
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • L

    Liu, Jia (第一作者)

    harbin med univ

  • N

    Nie, Chunsheng (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417